Novacyt S.A. (LON:NCYT – Get Free Report) was down 2.6% during trading on Wednesday . The company traded as low as GBX 56 ($0.73) and last traded at GBX 57.30 ($0.74). Approximately 33,852 shares traded hands during trading, a decline of 94% from the average daily volume of 572,561 shares. The stock had previously closed at GBX 58.80 ($0.76).
Novacyt Stock Performance
The company has a market cap of £40.26 million, a price-to-earnings ratio of -109.62 and a beta of -1.86. The company has a debt-to-equity ratio of 18.67, a quick ratio of 4.46 and a current ratio of 4.04. The stock’s fifty day simple moving average is GBX 71.73 and its two-hundred day simple moving average is GBX 61.50.
Novacyt Company Profile
Novacyt SA, together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments.
Featured Articles
- Five stocks we like better than Novacyt
- Want to Profit on the Downtrend? Downtrends, Explained.
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Invest in the Best Canadian Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Dividend Payout Ratio Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
